Scholar Rock Holding Corporation Common Stock (SRRK) Stock Price

SRRKStock

$39.90+35.53%52W

Market Cap$4.86B

P/E—

PEG Ratio—

Div yield—

Beta0.77

SRRK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-29.38%

Price vs S&P 500 (4W)-15.83%

VGM Score36.03

Book Value / Share (Quarterly)$2.09

P/TBV (Annual)3.25x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.44

Price vs S&P 500 (YTD)-21.35%

Net Profit Margin (TTM)-236.96%

EPS (TTM)$-3.30

10-Day Avg Trading Volume2.02M

EPS Excl Extra (TTM)$-3.30

EPS (Annual)$-2.47

ROI (Annual)-58.81%

Net Profit Margin (5Y Avg)-1236.36%

Cash / Share (Quarterly)$4.05

ROA (Last FY)-51.86%

EBITD / Share (TTM)$-3.27

ROE (5Y Avg)-60.37%

Operating Margin (TTM)-231.80%

Cash Flow / Share (Annual)$-2.77

P/B Ratio19.15x

P/B Ratio (Quarterly)25.97x

Net Income / Employee (Annual)$-852,200

EV / Revenue (TTM)97.64x

Net Interest Coverage (TTM)-809.50x

ROA (TTM)-86.60%

EPS Incl Extra (Annual)$-2.47

Current Ratio (Annual)6.95x

Quick Ratio (Quarterly)6.84x

3-Month Avg Trading Volume1.61M

52-Week Price Return35.53%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.98

P/S Ratio (Annual)146.41x

Asset Turnover (Annual)0.09x

52-Week High$61.76

Operating Margin (5Y Avg)-1238.26%

EPS Excl Extra (Annual)$-2.47

CapEx CAGR (5Y)-31.83%

Tangible BV CAGR (5Y)36.11%

26-Week Price Return-19.48%

Quick Ratio (Annual)6.68x

13-Week Price Return-24.52%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)7.02x

Enterprise Value$4.62B

Asset Turnover (TTM)0.16x

Book Value / Share Growth (5Y)-21.57%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-405.24%

Cash / Share (Annual)$3.39

3-Month Return Std Dev48.93%

Net Income / Employee (TTM)$-1,404,400

ROE (Last FY)-66.81%

EPS Basic Excl Extra (Annual)$-2.47

Receivables Turnover (TTM)1.23x

Total Debt / Equity (Quarterly)0.77x

EPS Incl Extra (TTM)$-3.30

ROI (TTM)-100.69%

P/S Ratio (TTM)102.73x

Pretax Margin (5Y Avg)-1236.36%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.04

Price vs S&P 500 (52W)20.00%

Year-to-Date Return-9.42%

5-Day Price Return-4.86%

EPS Normalized (Annual)$-2.47

ROA (5Y Avg)-41.66%

Net Profit Margin (Annual)-405.24%

Month-to-Date Return-17.43%

Cash Flow / Share (TTM)$-1.95

EBITD / Share (Annual)$-2.51

Operating Margin (Annual)-404.85%

LT Debt / Equity (Annual)0.41x

ROI (5Y Avg)-50.42%

LT Debt / Equity (Quarterly)0.77x

EPS Basic Excl Extra (TTM)$-3.30

P/TBV (Quarterly)5.05x

P/B Ratio (Annual)18.30x

Pretax Margin (TTM)-236.96%

Book Value / Share (Annual)$2.26

Price vs S&P 500 (13W)-27.20%

Beta0.77x

P/FCF (Annual)210.54x

Revenue / Share (TTM)$0.00

ROE (TTM)-159.12%

52-Week Low$27.07

vGradeF

mGradeC

vgmGradeD

SRRK Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.84	-$0.84	+0.33%(+$0.00)
Q1 2026	May 7, 2026	-$0.78	-$0.83	-6.32%(-$0.05)
Q4 2025	Mar 3, 2026	-$0.88	-$0.88	+0.29%(+$0.00)
Q3 2025	Nov 14, 2025	-$0.84	-$0.90	-7.76%(-$0.06)
Q2 2025	Aug 6, 2025	-$0.67	-$0.98	-47.15%(-$0.31)

SRRK Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.33

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About Scholar Rock Holding Corporation Common Stock

Scholar Rock is a biopharmaceutical company developing treatments for rare neuromuscular diseases, with a focus on Spinal Muscular Atrophy. Its lead candidate, apitegromab, is in clinical development with both intravenous and subcutaneous formulations. The company's pipeline also includes SRK-439, a myostatin inhibitor in development for rare neuromuscular indications.